These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21707530)

  • 21. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.
    Ravaud A; de la Fouchardière C; Asselineau J; Delord JP; Do Cao C; Niccoli P; Rodien P; Klein M; Catargi B
    Oncologist; 2010; 15(2):212-3; author reply 214. PubMed ID: 20189981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
    Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
    Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
    [No Abstract]   [Full Text] [Related]  

  • 23. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
    DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Cabebe E; Wakelee H
    Drugs Today (Barc); 2006 Jun; 42(6):387-98. PubMed ID: 16845442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
    Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
    CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sunitinib therapy in metastatic papillary thyroid cancer.
    Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
    Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of sunitinib on human thyroid cancer cells.
    Grosse J; Warnke E; Pohl F; Magnusson NE; Wehland M; Infanger M; Eilles C; Grimm D
    Cell Physiol Biochem; 2013; 32(1):154-70. PubMed ID: 23867310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
    Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib in the Treatment of Thyroid Cancer.
    Ferrari SM; Centanni M; Virili C; Miccoli M; Ferrari P; Ruffilli I; Ragusa F; Antonelli A; Fallahi P
    Curr Med Chem; 2019; 26(6):963-972. PubMed ID: 28990511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of sunitinib in gastrointestinal cancers other than GIST.
    Grávalos C; Grande E; Gasent JM
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):36-43. PubMed ID: 20133148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
    Khosravan R; Motzer RJ; Fumagalli E; Rini BI
    Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early development of sunitinib in hepatocellular carcinoma.
    Zhu AX; Raymond E
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
    D'Agostino M; Voce P; Celano M; Sponziello M; Moretti S; Maggisano V; Verrienti A; Durante C; Filetti S; Puxeddu E; Russo D
    Thyroid; 2012 Feb; 22(2):138-44. PubMed ID: 22191389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
    Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
    Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.